Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs MasTec Inc (MTZ) Price & Performance

Quest Diagnostics IncTrade
MasTec IncTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs MasTec Inc — how do they compare? Quest Diagnostics Inc trades at $230.98 (market cap $25.48B), while MasTec Inc trades at $212.75 (market cap $17.40B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while MasTec Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and MasTec Inc for 23 Days on average.

DGXMTZ
Market Cap
$25.48B$17.40B
Volume
941,8661,415,821
Sector
HealthIndustrials
52-Week High
$247.45$437.51
52-Week Low
$173.49$190.08
Typical Hold Time
56 Days23 Days
Enterprise Value
$31.23B$20.32B
Dividend Yield
1.49%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.

DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.

MasTec Inc

MasTec (MTZ) trades at $216.11, down 3.25% on the day, with technical indicators showing a bearish trend as the stock trades below key moving averages. The company maintains strong fundamentals with revenue growth from $14.3B in 2025 to $16.1B projected for 2026, and net income improving to $494M. Recent news highlights MTZ's positioning in infrastructure investment cycles, particularly in power delivery and data center markets, supported by a record $21.4B backlog.

The outlook remains positive given analyst consensus of 32 Buy ratings and a $408.58 price target, representing 89% upside potential. Key risks include premium valuation metrics (P/E 34.5), weak cash flow trends, and communications segment softness. The stock's current discount to analyst targets presents a compelling opportunity if execution improves.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DGX

No sentiment data available yet.

MTZ
98% Buy2% Sell
Avg holding period · 23 Days

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX →

About MasTec Inc

MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.

Read more on MTZ →